Browse BLK

Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Lipid-anchor Note=Present and active in lipid rafts. Membrane location is required for the phosphorylation of CD79A and CD79B (By similarity).
Domain PF07714 Protein tyrosine kinase
PF00017 SH2 domain
PF00018 SH3 domain
Function

Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling. B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors. Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation. Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor. Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207'. Phosphorylates also the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C. With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation. Contributes also to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation. In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose.

> Gene Ontology
 
Biological Process GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0006909 phagocytosis
GO:0009306 protein secretion
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030100 regulation of endocytosis
GO:0032024 positive regulation of insulin secretion
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0042886 amide transport
GO:0043254 regulation of protein complex assembly
GO:0046777 protein autophosphorylation
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050764 regulation of phagocytosis
GO:0050796 regulation of insulin secretion
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0060627 regulation of vesicle-mediated transport
GO:0071800 podosome assembly
GO:0071801 regulation of podosome assembly
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:1902115 regulation of organelle assembly
GO:1903532 positive regulation of secretion by cell
GO:1904951 positive regulation of establishment of protein localization
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004715 non-membrane spanning protein tyrosine kinase activity
Cellular Component GO:0009898 cytoplasmic side of plasma membrane
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0031234 extrinsic component of cytoplasmic side of plasma membrane
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-168256: Immune System
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between BLK and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of BLK in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of BLK in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.440.414
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.5790.0628
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4040.585
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1120.852
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1350.923
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0810.961
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9880.2
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1390.297
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.050.384
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1290.0304
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7750.264
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2230.508
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of BLK in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of BLK. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of BLK. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by BLK.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of BLK. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of BLK expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between BLK and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolBLK
NameBLK proto-oncogene, Src family tyrosine kinase
Aliases MGC10442; B lymphoid tyrosine kinase; MODY11; BLK nonreceptor tyrosine kinase; b lymphocyte kinase; p55-Blk; ......
Chromosomal Location8p23-p22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting BLK collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.